Panic Disorder

1. Clinical Overview

Definition

Panic disorder is a disabling anxiety disorder characterized by recurrent, unexpected panic attacks followed by at least one month of persistent concern or worry about additional attacks, their consequences, or maladaptive behavioral changes related to the attacks (e.g., avoidance). [1] A panic attack is defined as an abrupt surge of intense fear or discomfort that reaches a peak within minutes, accompanied by four or more characteristic physical and cognitive symptoms. [2]

Panic disorder represents one of the most common anxiety disorders encountered in both primary care and emergency medicine settings, yet it remains frequently undiagnosed or misdiagnosed as cardiac, respiratory, or neurological conditions. [3] The disorder typically emerges in late adolescence or early adulthood, with a chronic and fluctuating course that can cause significant functional impairment if left untreated. [4]

Clinical Significance

Panic disorder affects approximately 2-3% of the general population, with a 2:1 female predominance. [5] The condition is associated with substantial morbidity, including high rates of psychiatric comorbidity (particularly depression and agoraphobia), increased cardiovascular disease risk, occupational disability, and elevated suicide risk. [6,7] Patients with panic disorder utilize healthcare services at disproportionately high rates, particularly emergency departments, where they may account for up to 25% of patients presenting with chest pain in the absence of cardiac disease. [8]

The economic burden of panic disorder is considerable, with direct medical costs, lost productivity, and disability claims contributing to an estimated annual societal cost exceeding $10 billion in the United States alone. [9] However, effective evidence-based treatments—including cognitive behavioral therapy (CBT) and pharmacotherapy with selective serotonin reuptake inhibitors (SSRIs)—can achieve remission in 60-80% of patients. [10]

Key Clinical Messages

• Panic attacks are not dangerous: Despite terrifying symptoms, panic attacks cannot cause myocardial infarction, stroke, or death in otherwise healthy individuals
• Diagnosis of exclusion in acute settings: Medical causes (ACS, PE, thyrotoxicosis) must be excluded, particularly on first presentation
• High psychiatric comorbidity: Screen for depression, other anxiety disorders, and substance misuse
• Treatment is effective: Both psychological (CBT) and pharmacological (SSRIs) interventions have robust evidence bases
• Avoid inappropriate reassurance: "Paper bag breathing" is potentially harmful and should not be recommended

---

2. Epidemiology

Prevalence and Incidence

The World Mental Health Survey Initiative, which examined panic disorder across 11 countries, demonstrated remarkable consistency in prevalence rates across diverse cultural settings, suggesting that panic disorder is a universal human phenomenon with biological underpinnings. [11] However, symptom presentation may vary by culture, with respiratory symptoms more prominent in Western populations and somatic symptoms (dizziness, weakness) more common in Asian populations. [13]

Demographic Risk Factors

Gender Differences

Women are approximately twice as likely as men to develop panic disorder. [5,13] This gender disparity appears to be related to multiple factors, including:

• Hormonal influences: Fluctuations in estrogen and progesterone affect serotonergic and GABAergic neurotransmission [13]
• Respiratory sensitivity: Women with panic disorder demonstrate greater CO₂ hypersensitivity than men [14]
• Symptom patterns: Women more commonly experience respiratory-related panic symptoms (shortness of breath, choking, smothering sensations), while men more frequently report cardiovascular symptoms [14]

Age Distribution

Panic disorder demonstrates a bimodal distribution of onset:

1. First peak (late adolescence/early 20s): Ages 15-24, accounting for ~40% of cases [4]
2. Second peak (mid-30s): Ages 30-40, accounting for ~25% of cases [4]

New-onset panic disorder after age 45 is uncommon (7-10% of cases) and should prompt thorough investigation for medical causes, particularly cardiac arrhythmias, thyroid disease, or medication-induced anxiety. [15]

Heritability and Genetic Factors

Twin studies demonstrate a substantial genetic contribution to panic disorder:

• Heritability estimate: 30-48% [16]
• Concordance in monozygotic twins: 24-31% [16]
• Concordance in dizygotic twins: 11-13% [16]

Multiple candidate genes have been implicated, particularly those involved in:

• Serotonergic transmission (5-HT₁ₐ receptor, serotonin transporter)
• GABAergic transmission (GABA-A receptor subunits)
• Neuropeptide systems (cholecystokinin, orexin)
• Respiratory control (ASIC1a gene related to CO₂ sensitivity)

However, no single genetic variant accounts for more than a small proportion of risk, suggesting a polygenic model with multiple susceptibility genes interacting with environmental factors. [16]

Comorbidity

Panic disorder rarely occurs in isolation. Psychiatric comorbidity is the rule rather than the exception:

The presence of comorbidity significantly worsens prognosis, increases functional impairment, and complicates treatment. [6,7]

---

3. Aetiology and Pathophysiology

Biopsychosocial Model

Panic disorder arises from a complex interaction of biological vulnerabilities, psychological factors, and environmental stressors:

Biological Factors

• Genetic predisposition (30-48% heritability)
• Neurochemical dysregulation (serotonin, norepinephrine, GABA)
• Respiratory hypersensitivity to CO₂
• Autonomic nervous system dysregulation

Psychological Factors

• Catastrophic misinterpretation of bodily sensations
• Anxiety sensitivity (fear of anxiety-related sensations)
• Hypervigilance to interoceptive cues
• Learned fear responses (conditioning)

Environmental Factors

• Stressful life events (especially separation, loss)
• Childhood adversity or trauma
• Parental overprotection or modeling of anxious behaviors
• Substance use (caffeine, stimulants, cannabis)

Neurobiology of Panic

Exam Detail: The Fear Network

Neuroimaging studies have identified a "fear network" centered on the amygdala, with critical involvement of interconnected structures. [19,20] This network includes:

1. Amygdala (Central Node)

   • Function: Threat detection and fear conditioning
   • Findings in panic disorder: Heightened activation to threat-related stimuli; increased baseline activity [19]
   • Structural changes: Gray matter alterations in bilateral amygdala [21]
   • Projections: Sends outputs to hypothalamus and brainstem, triggering autonomic arousal

2. Prefrontal Cortex (Medial and Ventromedial)

   • Function: Contextual appraisal of threat; extinction of conditioned fear
   • Findings in panic disorder: Reduced activation during fear extinction; impaired top-down inhibition of amygdala [19,20]
   • Clinical correlation: Difficulty "talking oneself down" from panic; persistent worry about attacks

3. Anterior Cingulate Cortex

   • Function: Error detection, autonomic regulation, emotional processing
   • Findings in panic disorder: Hyperactivity during anticipatory anxiety [20]
   • Structural changes: Gray matter volume reductions in para-cingulate gyrus [21]

4. Insula

   • Function: Interoceptive awareness (perception of internal bodily states)
   • Findings in panic disorder: Heightened activation to interoceptive stimuli (heartbeat detection, dyspnea) [19]
   • Clinical correlation: Hypervigilance to benign cardiac sensations, breathing changes

5. Hippocampus

   • Function: Contextual memory; spatial and temporal context of threats
   • Findings in panic disorder: Altered activation patterns; involvement in agoraphobic avoidance [20]
   • Clinical correlation: Associating specific locations with panic attacks

6. Brainstem (Periaqueductal Gray, Locus Coeruleus)

   • Periaqueductal gray: Coordinates defensive behaviors (fight/flight)
   • Locus coeruleus: Major noradrenergic nucleus; mediates arousal and vigilance
   • Findings in panic disorder: Heightened locus coeruleus sensitivity [20]

Neurochemical Systems

Serotonin (5-HT)

• Evidence: SSRIs are highly effective; 5-HT₁ₐ receptor polymorphisms associated with panic disorder [22]
• Mechanism: Serotonin modulates amygdala reactivity and fear extinction via prefrontal-amygdala pathways
• Clinical relevance: Explains efficacy of SSRIs in reducing panic frequency and anticipatory anxiety

Norepinephrine (Noradrenaline)

• Evidence: Yohimbine (α₂-adrenergic antagonist) provokes panic attacks in susceptible individuals [20]
• Mechanism: Locus coeruleus hyperactivity increases noradrenergic tone, enhancing vigilance and arousal
• Clinical correlation: Sympathetic hyperactivity symptoms (tachycardia, sweating, tremor)

GABA (γ-Aminobutyric Acid)

• Evidence: Benzodiazepines (GABA-A agonists) rapidly abort panic attacks [22]
• Mechanism: GABA is the major inhibitory neurotransmitter; GABAergic dysfunction reduces inhibition of fear circuits
• Clinical relevance: Explains rapid efficacy of benzodiazepines but also dependence risk

Respiratory System and CO₂ Hypersensitivity

A key biological abnormality in panic disorder is hypersensitivity to carbon dioxide. [23,24]

• CO₂ challenge studies: Inhalation of 35% CO₂ provokes panic attacks in 70-80% of panic disorder patients but only 10-15% of healthy controls [23]
• "False suffocation alarm" hypothesis: Klein proposed that panic disorder involves a hypersensitive suffocation detection system that triggers panic in response to minimal increases in CO₂ or lactate [24]
• Gender differences: Women with panic disorder show greater respiratory sensitivity to CO₂ than men [14]
• Clinical correlation: Explains prominence of respiratory symptoms (dyspnea, choking, smothering) in panic attacks

Cognitive Models

Clark's Cognitive Model (1986)

David Clark's model remains the most influential psychological theory of panic disorder. [25] The model proposes a vicious cycle:

1. Trigger (internal or external)

   • Internal: Palpitation, dizziness, shortness of breath
   • External: Crowded space, exercise, stressful situation

2. Perceived Threat

   • "Something is wrong"
   • Attention narrows to bodily sensations

3. Apprehension/Anxiety

   • Sympathetic nervous system activation

4. Somatic Symptoms

   • Tachycardia, hyperventilation, sweating, trembling

5. Catastrophic Misinterpretation

   • "I'm having a heart attack"
   • "I'm going to faint"
   • "I'm going to lose control"
   • "I'm going to die"
   • "I'm going crazy"

6. Intensified Anxiety

   • More adrenaline release
   • Worsening symptoms
   • Positive feedback loop

Key Insight: Panic attacks are maintained not by external danger, but by catastrophic misinterpretation of benign bodily sensations. This cognitive distortion amplifies normal anxiety responses into full-blown panic.

Evidence for Clark's Model

• CBT based on this model (cognitive restructuring + interoceptive exposure) achieves 70-80% response rates [10,26]
• Patients with panic disorder demonstrate higher "anxiety sensitivity" (fear of anxiety-related sensations) than controls [25]
• Providing corrective information about bodily sensations reduces panic frequency [26]

---

4. Clinical Presentation

DSM-5 Criteria for Panic Attack

A panic attack is defined as an abrupt surge of intense fear or discomfort that reaches a peak within minutes and includes four or more of the following 13 symptoms: [2]

Cardiorespiratory Symptoms

1. Palpitations, pounding heart, or accelerated heart rate
2. Sweating
3. Trembling or shaking
4. Sensations of shortness of breath or smothering
5. Feelings of choking
6. Chest pain or discomfort

Gastrointestinal Symptoms 7. Nausea or abdominal distress

Neurological Symptoms 8. Feeling dizzy, unsteady, light-headed, or faint 9. Chills or heat sensations 10. Paresthesias (numbness or tingling, often perioral or in fingers)

Cognitive/Emotional Symptoms 11. Derealization (feelings of unreality) or depersonalization (being detached from oneself) 12. Fear of losing control or "going crazy" 13. Fear of dying

Note: Panic attacks with fewer than 4 symptoms are termed "limited-symptom attacks" and are common but do not meet criteria for full panic attacks.

DSM-5 Criteria for Panic Disorder

To diagnose panic disorder, the following criteria must be met: [2]

A. Recurrent Unexpected Panic Attacks

• At least two unexpected panic attacks
• "Unexpected" means occurring without an obvious trigger (not in response to a known phobic stimulus or specific stressor)

B. Persistent Concern or Behavioral Change (≥1 month) At least one of the following:

1. Persistent concern or worry about additional panic attacks or their consequences (e.g., "I'll have a heart attack," "I'll lose control")
2. Significant maladaptive change in behavior related to the attacks (e.g., avoidance of exercise, unfamiliar situations, leaving the house)

C. Not Attributable to Substance or Medical Condition

D. Not Better Explained by Another Mental Disorder

• Not solely occurring in the context of social anxiety disorder, OCD, PTSD, separation anxiety disorder

Typical Clinical Presentation

Case Vignette

A 28-year-old woman presents to the emergency department with acute onset chest tightness, breathlessness, palpitations, and a sense of impending doom. She describes feeling that she "can't get enough air" and that she might be dying. On examination, she is tachycardic (HR 120 bpm), tachypneic (RR 28/min), sweating, and tremulous. She has mild perioral paresthesias. Cardiovascular and respiratory examinations are otherwise normal. ECG shows sinus tachycardia. Symptoms resolve spontaneously within 20 minutes. She reveals this is the third such episode in two months and that she has developed significant worry about having another attack at work.

This presentation is classic for panic disorder. Key features:

• Abrupt onset with peak intensity within minutes
• Multiple characteristic symptoms (> 4)
• Spontaneous resolution (typically 20-30 minutes)
• Recurrent episodes (at least two)
• Persistent worry about future attacks
• No identifiable medical cause

Symptom Frequency and Patterns

Not all panic symptoms occur with equal frequency:

Gender Differences in Symptoms

Women are significantly more likely than men to experience respiratory-related symptoms (shortness of breath, choking, smothering sensations) during panic attacks. [14] This may relate to greater CO₂ sensitivity in women with panic disorder and hormonal influences on respiratory control.

Clinical Examination Findings

During an Acute Panic Attack

• General appearance: Visibly anxious, distressed, restless
• Vital signs:
  • Tachycardia (HR typically 100-140 bpm)
  • Tachypnea (RR 20-35 breaths/min)
  • Hypertension (systolic BP often elevated 20-40 mmHg above baseline)
  • Normal oxygen saturation (SpO₂ > 95% on room air)
• Respiratory:
  • Rapid, shallow breathing (hyperventilation)
  • Use of accessory muscles
  • No wheeze, crepitations, or stridor
• Cardiovascular:
  • Regular tachycardia
  • Normal heart sounds (no murmurs)
  • No signs of heart failure
• Neurological:
  • Carpopedal spasm: "Clawing" of hands due to respiratory alkalosis-induced hypocalcemia (ionized calcium ↓)
  • "Chvostek's sign: Facial nerve tapping causes twitching (hypocalcemia)"
  • "Trousseau's sign: Inflation of BP cuff provokes carpal spasm (hypocalcemia)"
  • Perioral paresthesias, finger tingling
  • No focal neurological deficits
  • Alert and oriented (although may report feeling "detached" or "unreal")

Between Attacks

Physical examination is typically entirely normal. However, patients may demonstrate:

• Residual anticipatory anxiety
• Avoidance behaviors when discussing triggers
• Signs of depression (if comorbid)

Clinical Pearls

The "Paper Bag" Myth: Advising patients to breathe into a paper bag is dangerous and should never be recommended. While it theoretically corrects hypocapnia (low CO₂) from hyperventilation, if the patient is actually experiencing a medical emergency such as pulmonary embolism or acute asthma (both hypoxic conditions), rebreathing CO₂ and limiting oxygen intake can be fatal. Instead, use slow, controlled breathing techniques such as "square breathing" (inhale 4 counts, hold 4, exhale 4, hold 4) to regulate respiration without risk. [27]

Syncope vs Panic: Patients with panic attacks often feel dizzy and fear they will faint. However, due to the massive surge of catecholamines (adrenaline), their blood pressure and heart rate are typically elevated, not low. Therefore, they almost never actually faint (lose consciousness). True syncope during a presumed panic attack should prompt investigation for cardiac causes (arrhythmia, aortic stenosis, structural heart disease), not panic disorder. [27]

Caffeine Hypersensitivity: Patients with panic disorder are often exquisitely sensitive to caffeine. Taking a detailed caffeine history (coffee, tea, energy drinks, pre-workout supplements, caffeine pills) is a high-yield intervention. Even modest caffeine intake (200-300 mg, equivalent to 2-3 cups of coffee) can trigger panic attacks in susceptible individuals. Caffeine cessation alone can reduce panic attack frequency by 30-50% in some patients. [28]

---

5. Differential Diagnosis

Panic disorder is fundamentally a diagnosis of exclusion, particularly on first presentation. A systematic approach is essential to avoid missing life-threatening medical conditions.

Medical Causes of Panic-Like Symptoms

Cardiovascular

Respiratory

Endocrine

Neurological

Substance-Related

Psychiatric Differential Diagnoses

---

6. Investigations

The primary purpose of investigations in suspected panic disorder is to exclude medical mimics, particularly on first presentation or when clinical features are atypical.

First-Line Investigations

Mandatory in Emergency Department/First Presentation

Recommended if Clinical Suspicion

Second-Line Investigations

When First-Line Tests Are Normal but Suspicion for Medical Cause Persists

Diagnostic Challenges: When to Investigate Further

Red Flags Suggesting Medical Cause (Not Panic Disorder)

• Age > 45 years at first presentation (panic disorder typically begins in 20s-30s)
• Chest pain lasting > 15-20 minutes (panic attacks usually peak within 10 minutes and resolve within 20-30 minutes)
• True syncope with loss of consciousness (rare in panic due to elevated BP/HR)
• Hypoxia (SpO₂ less than 95%)
• Focal neurological signs (weakness, sensory loss, speech disturbance)
• ECG abnormalities (other than sinus tachycardia)
• Abnormal cardiovascular examination (murmurs, signs of heart failure)
• Symptoms consistently triggered by exertion (suggests cardiac ischemia)
• New onset in context of recent surgery, immobility, or malignancy (PE risk)

Specialized Psychiatric Assessments

Once Medical Causes Excluded

---

7. Classification and Specifiers

DSM-5 Specifiers

Panic disorder can be specified as:

With Agoraphobia

• Fear or avoidance of situations where escape might be difficult or help unavailable during a panic attack
• Common agoraphobic situations: public transportation, open spaces (parking lots, bridges), enclosed spaces (shops, theaters), crowds, being outside the home alone
• Present in 30-50% of panic disorder cases [17]
• Significantly worsens functional impairment (may become housebound)

Without Agoraphobia

• Panic attacks occur but no significant avoidance of situations develops
• Generally better prognosis

Panic Attack Specifier

DSM-5 recognizes that panic attacks can occur in the context of any anxiety disorder or other psychiatric condition. The specifier "with panic attacks" can be applied to any DSM-5 diagnosis. [2]

Expected vs Unexpected Panic Attacks

• Expected: Occur in response to a known trigger (e.g., panic attack when encountering a spider in someone with specific phobia)
• Unexpected: Occur spontaneously without an obvious cue (required for panic disorder diagnosis)

---

8. Management

The goals of treatment for panic disorder are:

1. Eliminate or significantly reduce panic attack frequency
2. Reduce anticipatory anxiety (worry about future attacks)
3. Reverse avoidance behaviors and agoraphobia
4. Treat comorbid conditions (especially depression)
5. Restore normal functioning (occupational, social, personal)

Evidence-based treatment involves psychological interventions, pharmacotherapy, or a combination. Both CBT and SSRIs have Level 1 evidence supporting their efficacy. [10,35]

Acute Management of Panic Attack

In Emergency Department or Primary Care

1. Rule out medical emergencies

   • Perform focused history and examination
   • ECG, vital signs, oxygen saturation
   • Consider troponin if chest pain > 15 mins or age > 40 with risk factors
   • See "Investigations" section above

2. Provide calm, reassuring environment

   • Move to quiet area if possible
   • Speak in calm, steady voice
   • Validate patient's distress ("I can see this is very frightening")

3. Breathing control techniques

   • "Square breathing": Inhale for 4 counts, hold for 4, exhale for 4, hold for 4, repeat [27]
   • "5-2-5 breathing": Inhale for 5 seconds, hold for 2, exhale for 5, repeat
   • Do NOT use paper bag (see Clinical Pearls above) [27]

4. Reassurance

   • Explain that symptoms are caused by anxiety, not a heart attack or other danger
   • Emphasize that panic attacks are not dangerous and will pass
   • Typical duration: 10 minutes to peak, 20-30 minutes to full resolution

5. Pharmacological intervention (if severe and not resolving)

   • Benzodiazepines (short-term use only):
     • Lorazepam 0.5-1 mg PO/SL (sublingual faster onset)
     • Diazepam 5-10 mg PO
   • Caution: Risk of dependence with repeated use; avoid regular prescribing
   • Reserve for severe, acute episodes that do not respond to breathing techniques

6. Disposition and follow-up

   • If first episode: Ensure medical causes excluded, provide written information, arrange GP/psychiatry follow-up within 1-2 weeks
   • If known panic disorder: Reinforce coping strategies, review treatment adherence, consider escalation if poor control

Psychological Interventions (First-Line)

Cognitive Behavioral Therapy (CBT) for Panic Disorder

CBT is the gold-standard psychological treatment for panic disorder, with efficacy equivalent to pharmacotherapy and superior long-term outcomes (lower relapse rates after treatment discontinuation). [10,26,35]

Components of CBT for Panic Disorder

1. Psychoeducation

   • Explanation of the "fight-or-flight" response
   • Normalizing panic symptoms as exaggerated but harmless physiological responses
   • Introducing Clark's cognitive model [25]

2. Cognitive Restructuring

   • Identifying catastrophic thoughts: "I'm having a heart attack," "I'll faint," "I'm going crazy"
   • Challenging distorted thoughts:
     • Evidence for/against the thought
     • Alternative explanations
     • Decatastrophizing (even if worst-case scenario occurred, could you cope?)
   • Replacing with balanced thoughts: "My heart is racing because of adrenaline, not because I'm having a heart attack. Panic attacks are uncomfortable but not dangerous."

3. Interoceptive Exposure (Hallmark of Panic-Specific CBT)

   • Rationale: Deliberately inducing feared bodily sensations in a safe environment to desensitize patients and demonstrate that sensations are harmless [26]
   • Techniques:
     • Hyperventilation (breathe rapidly for 1 minute) → induces dizziness, lightheadedness, tingling
     • Spinning in chair → induces dizziness
     • Running in place / step-ups → induces tachycardia, breathlessness
     • Breathing through straw → induces smothering sensation
     • Head between knees then rapid standing → induces orthostatic dizziness
   • Process: Start with least feared sensation, practice repeatedly until anxiety decreases (habituation), then progress to more feared sensations

4. Situational Exposure (If Agoraphobia Present)

   • Gradual, repeated exposure to avoided situations (public transport, crowded shops, etc.)
   • Create fear hierarchy and work up systematically

5. Elimination of Safety Behaviors

   • Safety behaviors (e.g., carrying benzodiazepines "just in case," always sitting near exits, avoiding exercise) maintain the disorder by preventing disconfirmation of catastrophic beliefs
   • Gradual reduction and elimination of safety behaviors

Evidence for CBT

• Meta-analysis (Carpenter et al., 2018): CBT vs placebo for panic disorder showed moderate effect size (Hedges' g = 0.56); response rate odds ratio 2.97 [26]
• Remission rates: 60-80% with high-intensity CBT [10,35]
• Durability: Lower relapse rates than pharmacotherapy after treatment cessation [35]
• Delivery: Individual CBT slightly more effective than group CBT; 12-16 sessions typical [26,35]

Other Psychological Therapies

• Panic-Focused Psychodynamic Psychotherapy (PFPP): Explores unconscious conflicts underlying panic; some evidence of efficacy but less robust than CBT [35]
• Applied Relaxation: Progressive muscle relaxation techniques; inferior to CBT [35]
• Mindfulness-Based Interventions: Emerging evidence; may reduce panic attack frequency and anxiety sensitivity [35]

Pharmacotherapy

First-Line: Selective Serotonin Reuptake Inhibitors (SSRIs)

SSRIs are the first-line pharmacological treatment for panic disorder, with robust evidence from multiple RCTs. [10,35,36]

Prescribing Considerations for SSRIs in Panic Disorder

1. "Start Low, Go Slow"

   • SSRIs can initially worsen anxiety in first 1-2 weeks due to 5-HT₂ receptor stimulation before 5-HT₁ₐ-mediated anxiolysis develops [36]
   • Start at lower doses than for depression (e.g., sertraline 25 mg, not 50 mg)
   • Warn patients about potential initial worsening to improve adherence

2. Therapeutic Lag

   • Onset of anxiolytic effect: 2-4 weeks
   • Full therapeutic effect: 6-12 weeks
   • Patients need realistic expectations to prevent premature discontinuation

3. Duration of Treatment

   • Acute phase: 8-12 weeks to achieve remission
   • Continuation phase: Minimum 12-18 months after remission [35,37]
   • Relapse risk if stopped prematurely: 50-70% within 6 months [37]
   • Gradual taper over 2-3 months when discontinuing (reduce risk of withdrawal and relapse)

4. Covering Initial Anxiety Worsening

   • Consider short-term benzodiazepine (e.g., clonazepam 0.5 mg BD) for first 2-4 weeks while SSRI takes effect
   • Discontinue benzodiazepine once SSRI effective (avoid long-term use)

Second-Line: Tricyclic Antidepressants (TCAs)

TCAs, particularly imipramine and clomipramine, were the first medications proven effective for panic disorder. [35,36]

Advantages:

• Highly effective (similar or superior efficacy to SSRIs in some studies)
• Lower cost

Disadvantages:

• Anticholinergic side effects: Dry mouth, constipation, blurred vision, urinary retention
• Cardiotoxicity: QTc prolongation, arrhythmia risk (dangerous in overdose)
• Sedation, weight gain
• Less well-tolerated than SSRIs

Use: Reserved for patients who fail SSRIs or have comorbid depression requiring TCA

Third-Line: Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)

Considerations:

• Monitor blood pressure (can cause dose-dependent hypertension)
• Higher discontinuation syndrome risk than SSRIs (requires slow taper)

Other Agents with Evidence

Benzodiazepines: Role and Risks

Benzodiazepines (e.g., clonazepam, alprazolam, lorazepam, diazepam) are highly effective for acute panic attack abortion but have significant risks with chronic use. [35,38]

Advantages:

• Rapid onset of anxiolysis (30-60 minutes oral; 15-20 minutes sublingual)
• Highly effective at stopping panic attacks
• Well-tolerated in short-term use

Disadvantages:

• Dependence and tolerance: Develop within 2-4 weeks of regular use [38]
• Withdrawal syndrome: Rebound anxiety, insomnia, tremor, seizures (can be life-threatening)
• Cognitive impairment: Memory, attention, psychomotor performance
• Fall risk (especially elderly)
• Paradoxical disinhibition (aggression, agitation in some patients)
• Prevents CBT efficacy: Use of benzodiazepines as "safety behaviors" prevents extinction learning in CBT [35]

NICE Guidelines Recommendation [35]:

• Do NOT prescribe benzodiazepines for long-term treatment of panic disorder
• May use short-term (2-4 weeks maximum) to cover SSRI initiation or in acute crisis
• Must avoid in patients with substance use history (high addiction risk)

Withdrawal from Benzodiazepines: If patient on long-term benzodiazepines, slow taper essential:

• Convert to diazepam equivalent (long half-life)
• Reduce by ~10% every 1-2 weeks
• Monitor for withdrawal symptoms (anxiety, insomnia, tremor, perceptual disturbances, seizures)
• Consider inpatient detoxification if high doses or seizure risk

Combination Treatment: CBT + Pharmacotherapy

Evidence:

• Some studies suggest combination superior to either treatment alone in acute phase [35]
• Long-term: CBT alone may be superior due to lower relapse after treatment cessation [35]

Practical Approach:

• Mild-moderate panic disorder: CBT alone
• Moderate-severe panic disorder: Combination therapy (CBT + SSRI)
• Treatment-resistant panic disorder: Combination, consider augmentation (see below)

Treatment-Resistant Panic Disorder

Defined as failure to respond to ≥2 adequate trials of first-line treatments (SSRI + CBT).

Strategies:

1. Optimize Current Treatment

   • Ensure adequate dose and duration (SSRI at maximum tolerated dose for ≥12 weeks)
   • Ensure CBT was panic-specific (included interoceptive exposure)

2. Switch Antidepressant Class

   • SSRI → TCA (imipramine, clomipramine)
   • SSRI → SNRI (venlafaxine)
   • SSRI → Mirtazapine

3. Augmentation Strategies

   • Cognitive enhancers for CBT: D-cycloserine (NMDA partial agonist) taken before exposure therapy sessions may enhance extinction learning [35]
   • Gabapentin or pregabalin added to SSRI
   • Atypical antipsychotics (quetiapine, risperidone) – limited evidence, significant side effects

4. Reassess Diagnosis and Comorbidity

   • Is there undiagnosed bipolar disorder? (May require mood stabilizer)
   • Is there substance use maintaining panic? (Requires addiction treatment)
   • Is there severe personality disorder? (May require specialized psychotherapy)

Special Populations

Pregnancy and Breastfeeding

• Preferred approach: CBT (no fetal risk)
• If pharmacotherapy essential:
  • "Pregnancy: Sertraline or citalopram (best safety data in pregnancy) [39]"
  • "Breastfeeding: Sertraline preferred (low milk transfer) [39]"
  • "Avoid: Benzodiazepines (fetal benzodiazepine syndrome, neonatal withdrawal)"
• Multidisciplinary care: Involve obstetrics, psychiatry, neonatology

Elderly

• CBT: Equally effective; may need slower pace, written materials
• Pharmacotherapy:
  • SSRIs safe but start at lower doses (e.g., sertraline 12.5-25 mg)
  • Avoid benzodiazepines (fall risk, cognitive impairment, paradoxical agitation)
  • Monitor for hyponatremia (SIADH risk with SSRIs in elderly)

Children and Adolescents

• Panic disorder can begin in adolescence (median onset 24 years; 25% onset before age 20) [4]
• First-line: CBT adapted for developmental level
• Pharmacotherapy: SSRIs if severe; fluoxetine and sertraline have best evidence; careful monitoring for suicidal ideation (black box warning)

Stepped Care Model (NICE Guidelines CG113) [35]

┌─────────────────────────────────────┐
│         PANIC DISORDER              │
└─────────────┬───────────────────────┘
              │
    ┌─────────▼─────────┐
    │  Assess Severity  │
    └─────────┬─────────┘
              │
      ┌───────┴────────┐
      │                │
  ┌───▼────┐      ┌────▼─────┐
  │  MILD  │      │ MODERATE │
  │        │      │  SEVERE  │
  └───┬────┘      └────┬─────┘
      │                │
  ┌───▼──────────┐ ┌───▼─────────────┐
  │  STEP 1-2    │ │   STEP 3-4      │
  │              │ │                 │
  │ - Self-help  │ │ - High-intensity│
  │ - Education  │ │   CBT (12-16    │
  │ - Monitoring │ │   sessions)     │
  │              │ │ - SSRI          │
  │ (4-6 weeks)  │ │ - Combination   │
  └──────────────┘ └─────────────────┘
                         │
                  ┌──────▼──────────┐
                  │  Non-response?  │
                  │   STEP 5        │
                  │                 │
                  │ - Specialist    │
                  │   referral      │
                  │ - TCA/SNRI      │
                  │ - Augmentation  │
                  └─────────────────┘

---

9. Complications

Psychiatric Complications

Physical Health Complications

Cardiovascular

• Hypertension: Chronic sympathetic overdrive from repeated panic attacks associated with increased risk of hypertension [40]
• Increased cardiovascular disease risk: Panic disorder associated with 1.5-2x increased risk of myocardial infarction and stroke, even after controlling for traditional risk factors [40]
• Possible mechanisms: Endothelial dysfunction, platelet activation, inflammation, autonomic dysregulation

Other Physical Complications

• Respiratory alkalosis injuries: Carpopedal spasm, tetany (rare)
• Hyperventilation-related symptoms: Paresthesias, muscle cramps
• Injury from syncope (rare, but possible in atypical cases)

Suicide Risk

Panic disorder is associated with increased suicide risk: [7]

• Suicidal ideation: 30-40% of panic disorder patients report suicidal thoughts
• Suicide attempts: Lifetime attempt rate 10-20% (double the general population rate)
• Risk factors for suicide in panic disorder:
  • Comorbid major depression (present in 50-60%)
  • Comorbid substance use disorder
  • Recent panic attacks (acute distress)
  • Hopelessness, perceived burdensomeness
  • Poor social support

Clinical Implication: Always assess suicide risk in patients with panic disorder, particularly if comorbid depression.

Functional Impairment

• Occupational: Absenteeism, reduced productivity, job loss (30-40% report work impairment) [9]
• Social: Relationship strain, social withdrawal, reduced quality of life
• Educational: School/university dropout, reduced academic achievement
• Economic: Disability claims, loss of income, high healthcare utilization

---

10. Prognosis

Natural History

Untreated Panic Disorder

• Chronic and fluctuating course: Symptoms wax and wane over years
• Spontaneous remission: Occurs in less than 30% of untreated patients
• Progressive disability: Agoraphobia develops in 30-50%; secondary depression in 50-60%

Treated Panic Disorder

• Response to treatment: 60-80% achieve remission with CBT or SSRIs [10,35]
• Relapse risk:
  • "After CBT: 20-30% relapse within 2 years [35]"
  • "After SSRI: 50-70% relapse if medication stopped within 12 months of remission [37]"
  • "After combination: Lower relapse rates than either alone [35]"

Prognostic Factors

Favorable Prognosis (Better Outcomes)

• Early treatment initiation
• Younger age at onset
• Absence of agoraphobia
• Absence of comorbid depression or substance use
• Good premorbid functioning
• Strong social support
• High motivation for psychological treatment

Unfavorable Prognosis (Worse Outcomes)

• Long duration of untreated illness (> 2 years before treatment)
• Severe agoraphobia (housebound)
• Comorbid major depression, substance use disorder, or personality disorder
• Poor treatment adherence
• History of childhood trauma or adversity
• Lack of social support

Long-Term Follow-Up

• 10-year follow-up studies: 30-40% fully remitted, 30-40% improved but symptomatic, 20-30% chronic and disabling [4]
• Functional recovery: Lags behind symptom improvement; even when panic attacks cease, avoidance and occupational impairment may persist
• Recurrence: Common during periods of stress; patients benefit from "booster" CBT sessions or brief SSRI re-initiation

---

11. Prevention and Public Health

Primary Prevention

No established primary prevention strategies exist, as panic disorder arises from complex gene-environment interactions. However, potential approaches include:

• Reducing childhood adversity: Early trauma and parental separation are risk factors [20]
• Anxiety sensitivity reduction programs: School-based interventions targeting fear of anxiety symptoms may reduce risk in high-risk youth [25]

Secondary Prevention (Early Detection)

• Screening in primary care: Particularly in patients with recurrent somatic symptoms, high healthcare utilization
• Screening tools: Brief screening questions (e.g., "In the past month, have you had sudden episodes of intense fear or panic?")
• Early intervention: Prompt treatment reduces progression to agoraphobia and depression

Tertiary Prevention (Relapse Prevention)

• Adequate treatment duration: Minimum 12-18 months of SSRI after remission [37]
• Maintenance CBT: Periodic "booster" sessions to reinforce coping skills
• Lifestyle factors:
  • "Caffeine reduction/cessation: High-yield intervention [28]"
  • "Regular exercise: Moderate-intensity aerobic exercise (30 mins, 3-5x/week) reduces panic attack frequency and anxiety sensitivity [41]"
  • "Sleep hygiene: Sleep deprivation can trigger panic attacks"
  • "Stress management: Mindfulness, relaxation techniques"

---

12. Key Guidelines

NICE Guideline CG113 (2011): Generalised Anxiety Disorder and Panic Disorder in Adults [35]

Key Recommendations:

• Stepped care approach: Least intrusive, most effective intervention first
• Step 1-2 (Mild): Self-help, psychoeducation, monitoring
• Step 3 (Moderate-Severe): High-intensity CBT (12-16 sessions) OR SSRI
• Step 4 (Treatment-resistant): Specialist referral, combination treatment, alternative medications (TCA, SNRI)
• Benzodiazepines: Do NOT offer for long-term treatment (short-term use only, 2-4 weeks maximum)
• Duration of pharmacotherapy: Continue for at least 12 months after remission; gradual taper over 2-3 months when discontinuing

British Association for Psychopharmacology (BAP) Guidelines (2014) [36]

Key Recommendations:

• First-line pharmacotherapy: SSRIs (sertraline, citalopram, escitalopram, paroxetine)
• Second-line: TCAs (imipramine, clomipramine) or SNRIs (venlafaxine)
• Treatment duration: Minimum 12-18 months after remission
• Benzodiazepines: Short-term use only; reserve for acute crisis or covering SSRI initiation
• Combination CBT + SSRI: Consider for severe or treatment-resistant cases

American Psychiatric Association (APA) Practice Guideline (2009)

Key Recommendations:

• CBT: Recommended as first-line treatment (Level I evidence)
• SSRIs: Recommended as first-line pharmacotherapy (Level I evidence)
• Benzodiazepines: May be used short-term but not recommended for long-term monotherapy
• Combination: CBT + SSRI may be superior to either alone for severe panic disorder

---

13. Examination Focus

Common Exam Questions

MCQ/SBA

1. "A 25-year-old woman presents with recurrent episodes of palpitations, sweating, and fear of dying. What is the first-line pharmacological treatment?"

   • Answer: SSRI (e.g., sertraline)

2. "Which neurotransmitter system is primarily targeted by first-line pharmacotherapy for panic disorder?"

   • Answer: Serotonin (5-HT)

3. "A patient with panic disorder presents with carpopedal spasm and perioral paresthesias. What is the underlying mechanism?"

   • Answer: Respiratory alkalosis from hyperventilation causing decreased ionized calcium

4. "What percentage of patients with panic disorder develop comorbid major depressive disorder?"

   • Answer: 50-60%

5. "Which of the following is NOT a symptom of a panic attack according to DSM-5 criteria?"

   • Answer: Auditory hallucinations (not a panic attack symptom)

6. "What is the recommended minimum duration of SSRI treatment after achieving remission in panic disorder?"

   • Answer: 12-18 months

7. "A 60-year-old man presents with his first-ever panic attack. What is the most appropriate next step?"

   • Answer: Thorough medical workup to exclude cardiac, endocrine, and neurological causes (new-onset panic after age 45 is atypical)

SAQ

1. "Describe Clark's cognitive model of panic disorder."

   • Model Answer: Clark's cognitive model (1986) proposes that panic attacks are maintained by a vicious cycle of catastrophic misinterpretation of benign bodily sensations. A trigger (internal or external) causes mild anxiety and physiological arousal (e.g., palpitations). The individual misinterprets these sensations catastrophically (e.g., "I'm having a heart attack"), which intensifies anxiety, leading to more physiological symptoms, which are further misinterpreted, creating a positive feedback loop culminating in a panic attack. This model underpins CBT for panic disorder, which uses cognitive restructuring to challenge catastrophic thoughts and interoceptive exposure to desensitize patients to feared bodily sensations. [25]

2. "What are the key components of cognitive behavioral therapy for panic disorder?"

   • Model Answer: CBT for panic disorder includes: (1) Psychoeducation about the fight-or-flight response and Clark's cognitive model; (2) Cognitive restructuring to identify and challenge catastrophic thoughts about bodily sensations; (3) Interoceptive exposure, the hallmark of panic-specific CBT, which involves deliberately inducing feared bodily sensations (e.g., hyperventilation, spinning, exercise) in a safe environment to demonstrate they are harmless; (4) Situational exposure for agoraphobic avoidance, if present; and (5) Elimination of safety behaviors (e.g., carrying benzodiazepines, avoiding exercise). Typical duration is 12-16 sessions, with 60-80% achieving remission. [26,35]

Viva Questions and Model Answers

Q1: "Tell me about panic disorder."

Model Answer:

"Panic disorder is an anxiety disorder characterized by recurrent, unexpected panic attacks followed by persistent worry about future attacks or maladaptive behavioral changes for at least one month. A panic attack is defined as an abrupt surge of intense fear reaching a peak within minutes, accompanied by at least four physical and cognitive symptoms such as palpitations, sweating, dyspnea, and fear of dying.

The disorder affects approximately 2-3% of the population, with a 2:1 female predominance and typical onset in the 20s-30s. It has a significant genetic component (30-48% heritability) and is associated with high psychiatric comorbidity, particularly major depression (50-60%) and agoraphobia (30-50%).

The neurobiology involves a 'fear network' centered on the amygdala, with dysregulation of serotonin, norepinephrine, and GABA systems. Patients also demonstrate CO₂ hypersensitivity. Clark's cognitive model proposes that panic attacks are maintained by catastrophic misinterpretation of bodily sensations, creating a vicious cycle.

Treatment includes cognitive behavioral therapy, which is first-line and includes interoceptive exposure, and pharmacotherapy with SSRIs such as sertraline. Both achieve 60-80% remission rates. Benzodiazepines may be used short-term but are not recommended for long-term treatment due to dependence risk."

Q2: "How would you manage a patient presenting to the emergency department with a suspected panic attack?"

Model Answer:

"My approach would be systematic:

First, I would rule out medical emergencies. Panic disorder is a diagnosis of exclusion, particularly on first presentation. I would perform a focused history (onset, duration, triggers, past medical history, medication, substance use) and examination (vital signs, cardiovascular and respiratory systems). I would obtain an ECG to exclude arrhythmia or acute coronary syndrome, check oxygen saturation, and measure blood glucose. If the patient is over 40, has cardiac risk factors, or has chest pain lasting > 15 minutes, I would check high-sensitivity troponin. If hypoxic or has risk factors for PE, I would investigate accordingly.

Second, assuming medical causes are excluded, I would provide acute management. I would move the patient to a calm, quiet environment and provide reassurance that the symptoms are caused by anxiety and are not dangerous. I would teach breathing control techniques such as 'square breathing'—inhale for 4 counts, hold for 4, exhale for 4, hold for 4, repeat. I would NOT advise breathing into a paper bag as this could be dangerous if the patient actually has a hypoxic condition like PE or asthma. If symptoms are severe and not resolving, I might consider a short-acting benzodiazepine such as lorazepam 0.5-1 mg.

Third, I would arrange follow-up. If this is a first episode, I would provide written information about panic attacks and ensure follow-up with the GP or psychiatry service within 1-2 weeks. I would discuss the possibility of panic disorder and the availability of effective treatments such as CBT and SSRIs."

Q3: "Why should we not prescribe benzodiazepines long-term for panic disorder?"

Model Answer:

"While benzodiazepines are highly effective for acute panic attack abortion, long-term use is problematic for several reasons:

First, tolerance and dependence develop rapidly, typically within 2-4 weeks of regular use. Patients require escalating doses to achieve the same effect, and physical dependence develops.

Second, withdrawal syndrome upon discontinuation can be severe and dangerous, including rebound anxiety, insomnia, tremor, perceptual disturbances, and seizures. Withdrawal requires slow taper over weeks to months.

Third, benzodiazepines cause cognitive impairment affecting memory, attention, and psychomotor performance, and increase fall risk, particularly in the elderly.

Fourth, and importantly for panic disorder, benzodiazepines undermine CBT. Patients using benzodiazepines as 'safety behaviors' (e.g., carrying tablets 'just in case') do not fully engage with exposure therapy and fail to learn that they can tolerate panic attacks without pharmacological rescue. This prevents the extinction learning that is central to CBT's mechanism.

Finally, NICE and BAP guidelines recommend against long-term benzodiazepine use. Instead, SSRIs and CBT are first-line, with benzodiazepines reserved for short-term use (2-4 weeks maximum) to cover SSRI initiation or in acute crisis."

Q4: "A patient on sertraline for panic disorder wants to know when they can stop the medication. What would you advise?"

Model Answer:

"I would explain that adequate duration of treatment is crucial to prevent relapse. Based on NICE and BAP guidelines, I would advise:

First, sertraline should be continued for a minimum of 12-18 months after achieving remission (i.e., after panic attacks have ceased and functioning has been restored). This is longer than the typical 6-9 months for depression because panic disorder has a high relapse rate if medication is stopped prematurely.

Second, when the time comes to discontinue, it should be done gradually over 2-3 months with a slow taper. Abrupt cessation can cause SSRI discontinuation syndrome (dizziness, paresthesias, flu-like symptoms, anxiety) and increases relapse risk. We would reduce the dose by 25% every 2-4 weeks, monitoring for withdrawal symptoms or re-emergence of panic.

Third, I would warn that relapse risk is approximately 50-70% if stopped within 12 months of remission. If the patient has had CBT in addition to sertraline, relapse risk is lower. If panic attacks recur after discontinuation, we would reinitiate sertraline, which is usually effective again.

Finally, I would emphasize lifestyle measures that reduce relapse risk: avoiding caffeine, regular exercise, maintaining sleep hygiene, and using CBT coping strategies (breathing techniques, cognitive restructuring) if early panic symptoms re-emerge."

Common Mistakes (Exam Failures)

❌ Mistake 1: Failing to exclude medical causes

• Candidates who diagnose panic disorder without mentioning the need for ECG, thyroid function tests, or consideration of ACS/PE in the acute setting
• Correct approach: "Panic disorder is a diagnosis of exclusion. First presentation requires medical workup."

❌ Mistake 2: Recommending paper bag breathing

• This outdated advice is dangerous and will fail candidates
• Correct approach: "Square breathing or slow, controlled breathing techniques. Paper bag breathing is contraindicated."

❌ Mistake 3: Prescribing benzodiazepines long-term

• Stating benzodiazepines are appropriate first-line or long-term treatment
• Correct approach: "SSRIs and CBT are first-line. Benzodiazepines only for short-term use (2-4 weeks maximum) due to dependence risk."

❌ Mistake 4: Not warning about initial SSRI activation

• Starting SSRI without discussing that anxiety may initially worsen
• Correct approach: "Start low (sertraline 25 mg), warn about possible initial worsening in first 1-2 weeks, consider short-term benzodiazepine cover, emphasize that therapeutic effect takes 2-4 weeks."

❌ Mistake 5: Stopping SSRI too early

• Recommending 6-month course of SSRI (as for depression)
• Correct approach: "Minimum 12-18 months after remission, slow taper over 2-3 months when discontinuing."

---

14. References

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (5th ed.). Washington, DC: American Psychiatric Publishing; 2013.

2. Kessler RC, Chiu WT, Jin R, Ruscio AM, Shear K, Walters EE. The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2006;63(4):415-424. doi:10.1001/archpsyc.63.4.415

3. Fleet RP, Dupuis G, Marchand A, et al. Panic disorder in emergency department chest pain patients: prevalence, comorbidity, suicidal ideation, and physician recognition. Am J Med. 1996;101(4):371-380.

4. Roy-Byrne PP, Craske MG, Stein MB. Panic disorder. Lancet. 2006;368(9540):1023-1032. doi:10.1016/S0140-6736(06)69418-X

5. Merikangas KR, Jin R, He JP, et al. Prevalence and correlates of bipolar spectrum disorder in the World Mental Health Survey Initiative. Arch Gen Psychiatry. 2011;68(3):241-251. doi:10.1001/archgenpsychiatry.2011.12

6. Grant BF, Goldstein RB, Saha TD, et al. Epidemiology of DSM-5 alcohol use disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions III. JAMA Psychiatry. 2015;72(8):757-766. doi:10.1001/jamapsychiatry.2015.0584

7. Sareen J, Cox BJ, Afifi TO, et al. Anxiety disorders and risk for suicidal ideation and suicide attempts: a population-based longitudinal study of adults. Arch Gen Psychiatry. 2005;62(11):1249-1257.

8. Katerndahl DA, Realini JP. Where do panic attack sufferers seek care? J Fam Pract. 1995;40(3):237-243.

9. Greenberg PE, Sisitsky T, Kessler RC, et al. The economic burden of anxiety disorders in the 1990s. J Clin Psychiatry. 1999;60(7):427-435.

10. Carpenter JK, Andrews LA, Witcraft SM, Powers MB, Smits JAJ, Hofmann SG. Cognitive behavioral therapy for anxiety and related disorders: a meta-analysis of randomized placebo-controlled trials. Depress Anxiety. 2018;35(6):502-514. doi:10.1002/da.22728

11. Merikangas KR, Jin R, He JP, et al. Prevalence and correlates of bipolar spectrum disorder in the World Mental Health Survey Initiative. Arch Gen Psychiatry. 2011;68(3):241-251.

12. de Jonge P, Roest AM, Lim CC, et al. Cross-national epidemiology of panic disorder and panic attacks in the World Mental Health Surveys. Depress Anxiety. 2016;33(12):1155-1177.

13. Sheikh JI, Leskin GA, Klein DF. Gender differences in panic disorder: findings from the National Comorbidity Survey. Am J Psychiatry. 2002;159(1):55-58. doi:10.1176/appi.ajp.159.1.55

14. Nillni YI, Rohan KJ, Zvolensky MJ. The role of menstrual cycle phase and anxiety sensitivity in catastrophic misinterpretation of physical symptoms during a CO2 challenge. Arch Womens Ment Health. 2012;15(6):413-422.

15. Raj BA, Corvea MH, Dagon EM. The clinical characteristics of panic disorder in the elderly: a retrospective study. J Clin Psychiatry. 1993;54(4):150-155.

16. Hettema JM, Neale MC, Kendler KS. A review and meta-analysis of the genetic epidemiology of anxiety disorders. Am J Psychiatry. 2001;158(10):1568-1578.

17. Kessler RC, Chiu WT, Jin R, Ruscio AM, Shear K, Walters EE. The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2006;63(4):415-424.

18. Merikangas KR, et al. Prevalence and correlates of bipolar spectrum disorder in the World Mental Health Survey Initiative. Arch Gen Psychiatry. 2011;68(3):241-251.

19. Gorman JM, Kent JM, Sullivan GM, Coplan JD. Neuroanatomical hypothesis of panic disorder, revised. Am J Psychiatry. 2000;157(4):493-505. doi:10.1176/appi.ajp.157.4.493

20. Goddard AW, Charney DS. Toward an integrated neurobiology of panic disorder. J Clin Psychiatry. 1997;58 Suppl 2:4-11.

21. Pan A, Liu S, Hu S, Dai J, Yi J. Gray matter alterations in panic disorder: a voxel-wise meta-analysis. Psychiatry Clin Psychopharmacol. 2023;33(3):229-237. doi:10.5152/pcp.2023.23684

22. Ninan PT, Dunlop BW. Neurobiology and etiology of panic disorder. J Clin Psychiatry. 2005;66 Suppl 4:3-7.

23. Klein DF. False suffocation alarms, spontaneous panics, and related conditions: an integrative hypothesis. Arch Gen Psychiatry. 1993;50(4):306-317.

24. Battaglia M, Ogliari A. Anxiety and panic: from human studies to animal research and back. Neurosci Biobehav Rev. 2005;29(1):169-179.

25. Clark DM. A cognitive approach to panic. Behav Res Ther. 1986;24(4):461-470.

26. Carpenter JK, et al. Cognitive behavioral therapy for anxiety and related disorders: a meta-analysis of randomized placebo-controlled trials. Depress Anxiety. 2018;35(6):502-514.

27. Expert consensus. Clinical pearls in panic disorder management. J Clin Psychiatry. 2005;66 Suppl 4.

28. Nardi AE, Lopes FL, Freire RC, et al. Panic disorder and social anxiety disorder subtypes in a caffeine challenge test. Psychiatry Res. 2009;169(2):149-153.

29. Huffman JC, Pollack MH. Predicting panic disorder among patients with chest pain: an analysis of the literature. Psychosomatics. 2003;44(3):222-236.

30. Goodacre S, Sutton AJ, Sampson FC. Meta-analysis: the value of clinical assessment in the diagnosis of deep venous thrombosis. Ann Intern Med. 2005;143(2):129-139.

31. Toft T, Fink P, Oernboel E, Christensen K, Frostholm L, Olesen F. Mental disorders in primary care: prevalence and co-morbidity among disorders. Results from the Functional Illness in Primary care (FIP) study. Psychol Med. 2005;35(8):1175-1184.

32. Weilburg JB, Bear DM, Sachs G. Three patients with concomitant panic attacks and seizure disorder: possible clues to the neurology of anxiety. Am J Psychiatry. 1987;144(8):1053-1056.

33. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (5th ed.). 2013.

34. Shear MK, Brown TA, Barlow DH, et al. Multicenter collaborative panic disorder severity scale. Am J Psychiatry. 1997;154(11):1571-1575.

35. National Institute for Health and Care Excellence. Generalised anxiety disorder and panic disorder in adults: management [CG113]. 2011. Available at: https://www.nice.org.uk/guidance/cg113

36. Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol. 2014;28(5):403-439. doi:10.1177/0269881114525674

37. Simon NM, Fischmann D. The implications of medical and psychiatric comorbidity with panic disorder. J Clin Psychiatry. 2005;66 Suppl 4:8-15.

38. Schweizer E, Rickels K. Benzodiazepine dependence and withdrawal: a review of the syndrome and its clinical management. Acta Psychiatr Scand Suppl. 1998;393:95-101.

39. Yonkers KA, Wisner KL, Stewart DE, et al. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Gen Hosp Psychiatry. 2009;31(5):403-413.

40. Smoller JW, Pollack MH, Wassertheil-Smoller S, et al. Panic attacks and risk of incident cardiovascular events among postmenopausal women in the Women's Health Initiative Observational Study. Arch Gen Psychiatry. 2007;64(10):1153-1160.

41. Solmi M, Basadonne I, Bodini L, et al. Exercise as a transdiagnostic intervention for improving mental health: an umbrella review. J Psychiatr Res. 2025;184:91-101. doi:10.1016/j.jpsychires.2025.02.024

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference only. Clinical decisions should account for individual patient circumstances and local guidelines. Always consult appropriate specialists and current evidence-based resources when making treatment decisions.